409 related articles for article (PubMed ID: 1967305)
1. Pentavalent technetium-99m (V)-DMSA uptake in a pheochromocytoma in a patient with Sipple's syndrome.
Adams BK; Fataar A; Byrne MJ; Levitt NS; Matley PJ
J Nucl Med; 1990 Jan; 31(1):106-8. PubMed ID: 1967305
[TBL] [Abstract][Full Text] [Related]
2. Sipple's syndrome with liver tumors examined by iodine-131 MIBG and technetium-99m(V)-DMSA.
Ohta H; Endo K; Fujita T; Koizumi M; Konishi J; Maki A; Mori K; Ozawa K; Inoue G; Nakano Y
J Nucl Med; 1988 Jun; 29(6):1130-5. PubMed ID: 2897436
[TBL] [Abstract][Full Text] [Related]
3. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors.
Limouris GS; Giannakopoulos V; Stavraka A; Toubanakis N; Vlahos L
Anticancer Res; 1997; 17(3B):1589-92. PubMed ID: 9179199
[TBL] [Abstract][Full Text] [Related]
4. Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP--an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid.
Clarke SE; Lazarus CR; Wraight P; Sampson C; Maisey MN
J Nucl Med; 1988 Jan; 29(1):33-8. PubMed ID: 2826723
[TBL] [Abstract][Full Text] [Related]
5. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma.
Verga U; Muratori F; Di Sacco G; Banfi F; Libroia A
Henry Ford Hosp Med J; 1989; 37(3-4):175-7. PubMed ID: 2576958
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and therapeutic potential of new radiopharmaceutical agents in medullary thyroid carcinoma.
Troncone L; Rufini V; De Rosa G; Testa A
Henry Ford Hosp Med J; 1989; 37(3-4):178-84. PubMed ID: 2576959
[TBL] [Abstract][Full Text] [Related]
7. Detection of metastatic medullary thyroid cancer with 131I-MIBG scans in Sipple's syndrome.
Itoh H; Sugie K; Toyooka S; Kawase M; Mukaino S; Hazama F; Endo K; Torizuka K; Nakao K; Imura H
Eur J Nucl Med; 1986; 11(12):502-4. PubMed ID: 2874028
[TBL] [Abstract][Full Text] [Related]
8. Pitfall of Sipple's syndrome diagnosis by 131I-metaiodobenzylguanidine (MIBG).
Talbot JN; Coutris G; Moulonguet M; Hoang C; Perniceni T; Milhaud G
J Nucl Med Allied Sci; 1987; 31(4):337-40. PubMed ID: 2895168
[No Abstract] [Full Text] [Related]
9. Poor results with technetium-99m (V) DMS and iodine-131 MIBG in the imaging of medullary thyroid carcinoma.
Hilditch TE; Connell JM; Elliot AT; Murray T; Reed NS
J Nucl Med; 1986 Jul; 27(7):1150-3. PubMed ID: 3014086
[TBL] [Abstract][Full Text] [Related]
10. Thyroid uptake of MIBG in Sipple's syndrome.
Perdrisot R; Rohmer V; Lejeune JJ; Bigorgne JC; Jallet P
Eur J Nucl Med; 1988; 14(1):37-8. PubMed ID: 2898364
[TBL] [Abstract][Full Text] [Related]
11. Imaging of medullary thyroid carcinoma and hyperfunctioning adrenal medulla using iodine-131 metaiodobenzylguanidine.
Ansari AN; Siegel ME; DeQuattro V; Gazarian LH
J Nucl Med; 1986 Dec; 27(12):1858-60. PubMed ID: 2878066
[TBL] [Abstract][Full Text] [Related]
12. Iodine 131 metaiodobenzylguanidine scintigraphy of medullary carcinoma of the thyroid.
Skowsky WR; Wilf LH
South Med J; 1991 May; 84(5):636-41. PubMed ID: 1852077
[TBL] [Abstract][Full Text] [Related]
13. Preparation and clinical evaluation of technetium-99m dimercaptosuccinic acid for tumour scintigraphy.
Hirano T; Tomiyoshi K; Zhang YJ; Ishida T; Inoue T; Endo K
Eur J Nucl Med; 1994 Jan; 21(1):82-5. PubMed ID: 8088289
[TBL] [Abstract][Full Text] [Related]
14. [The assessment of clinical usefulness of 131I-MIBG scintigraphy for localization of tumors of sympathetic and adrenomedullary origin--a report of multicenter phase III clinical trials].
Sasaki Y; Kubo A; Kusakabe K; Masaki H; Endo K; Yamashita M; Nakajo M; Kaneko M
Kaku Igaku; 1992 Sep; 29(9):1083-98. PubMed ID: 1360549
[TBL] [Abstract][Full Text] [Related]
15. [Scintigraphy of medullary carcinoma of the thyroid by new radiopharmaceuticals].
Tada J; Konishi J; Torizuka K; Makimoto K; Miyauchi A
Rinsho Hoshasen; 1984 Sep; 29(9):1043-4. PubMed ID: 6096600
[No Abstract] [Full Text] [Related]
16. Obstructive hydronephrosis with I-131 MIBG accumulation mimicking huge pheochromocytoma: a diagnostic pitfall found with Tc-99m MDP imaging.
Kao PF; Tzen KY; Huang MJ; You DL
Clin Nucl Med; 1996 Dec; 21(12):994-5. PubMed ID: 8957629
[No Abstract] [Full Text] [Related]
17. Multiple endocrine neoplasia type 2 with malignant pheochromocytoma--long term follow-up of a case by 131I-meta-iodobenzylguanidine scintigraphy.
Namba H; Kondo H; Yamashita S; Kimura H; Yokoyama N; Tsuruta M; Sato A; Izumi M; Kinoshita H; Hakariya S
Ann Nucl Med; 1992 May; 6(2):111-5. PubMed ID: 1352456
[TBL] [Abstract][Full Text] [Related]
18. [Clinical applications of 131I-meta iodobenzylguanidine (131I-MIBG) scintigraphy in Japan].
Izumi M; Kakezono F; Nagayama Y; Kiriyama T; Yokoyama N; Yamashita S; Morita S; Hirayu H; Kubo I; Ohtakara S
Kaku Igaku; 1986 Feb; 23(2):145-52. PubMed ID: 2872353
[No Abstract] [Full Text] [Related]
19. Radionuclide imaging in medullary thyroid carcinoma: evaluation of two new radiopharmaceuticals.
Clarke SE; Lazarus CR; Maisey MN
Henry Ford Hosp Med J; 1987; 35(2-3):124-6. PubMed ID: 2826368
[No Abstract] [Full Text] [Related]
20. Pitfalls in scintigraphic detection of neuroendocrine tumours.
Feggi L; Degli Uberti E; Pansini GC; Transforini G; Prandini N; Ambrosio MR; D'Urso AR; Faggioli R
Eur J Nucl Med; 1992; 19(3):214-8. PubMed ID: 1315279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
